国药一致

China National Accord Medicines released a preliminary 2025 performance report. Revenue slightly declined 1.29% to RMB 73.416 billion, but net profit surged 76.8% to RMB 1.136 billion. Basic earnings per share were RMB 2.04.

AI 생성: 요약은 링크된 출처를 바탕으로 AI가 작성했습니다. AI 활용 방식